Related Experiment Video
Updated: Sep 17, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Advances in the study of sodium-glucose cotransporter 2 inhibitors for peritoneal dialysis
Juan Chen1,2, Jie Yang1,2, Bengang Huo1,2
1Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China.
Abstract:
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a novel class of hypoglycemic agents widely used in clinical practice in recent years. Recent studies have revealed that sodium-glucose cotransporter 2 is expressed in human peritoneal mesothelial and vascular endothelial cells, suggesting its potential involvement in peritoneal injury and ultrafiltration failure during peritoneal dialysis. Treatment with SGLT2is may alleviate peritoneal inflammation, fibrosis, and angiogenesis, improving ultrafiltration failure. Therefore, SGLT2is hold promise as a novel therapeutic approach for mitigating peritoneal injury and enhancing peritoneal function. A growing number of clinical studies are emerging, although most still remain in the early stages. This review highlights the role and mechanisms of SGLT2is in addressing peritoneal injury and ultrafiltration failure, with the aim of offering new therapeutic strategies to prevent complications associated with peritoneal dialysis.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucose Absorption Into the Small Intestine
Transcellular Transport of Solutes
Peritoneal Dialysis I: Introduction and Procedure
